• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA warns Invacare on burning beds

FDA warns Invacare on burning beds

January 5, 2011 By MedCity News

IVC logo

Invacare Corp. (NYSE:IVC) was slapped with a warning letter by federal regulators for failing to adequately investigate reports of fires and sparks from electric beds that in some cases allegedly resulted in patient deaths.

The warning letter from the Food & Drug Administration contains several disturbing consumer complaints related to Invacare’s adjustable beds, including one in April about a fire that started at the foot of a bed and resulted in a consumer’s death.

One complaint from June involved an Invacare bariatric bed that caught fire, resulting in two patients being taken to the hospital and treated for smoke inhalation and chest pain. “Visible flames were observed. However, when the unit was unplugged the fire went out,” the letter stated.

MedCity News logo

The letter, addressed to Invacare chairman A. Malachi Mixon III, is dated Dec. 15, but was posted on the FDA’s website Tuesday morning. The news sent Invacare’s shares tumbling about 4 percent yesterday, to $29.29. IVC shares fell nearly a percent in early morning trading today, but soon recouped the losses.

Invacare fully stands behind the safety of its products, the company said in prepared remarks. “The FDA warning letter does not state that our products are unsafe nor has it impacted our production,” CEO Gerald Blouch said. “The letter is related to documentation procedures,” he said.

In addition to sparks and flames, Invacare’s adjustable beds were the target of complaints after consumers apparently became trapped in the beds’ rails. One complaint involved the “bed entrapment death” of an 11-year-old child, according to the letter.

An Invacare spokeswoman stressed that the consumer complaints detailed in the warning letter were “allegations.”

Warning letters generally are considered by the FDA to be informal and advisory. The letters are a fairly routine part of doing business for medical device firms. However, the grisly nature of some of the complaints relating to Invacare’s beds indicates that this affair may not fade away as quickly as the company no doubt wishes it would.

The violations cited by the FDA came to light during an August inspection of a plant in Sanford, Florida. Invacare was cited for a host of record-keeping violations at the plant, including failing to document the manufacturing steps needed to prevent the production of faulty or “nonconforming” product.

After the inspection that uncovered the violations, Invacare addressed the issues with the FDA. However, the letter repeatedly states that Invacare’s response “is not adequate,” because the company in some cases didn’t document what corrective actions it would take.

The FDA’s letter gave Invacare 15 days to respond with a list of steps taken to address the violations. Failure to do so could result in punishment from the FDA that could include fines, seizure or injunction.

Invacare said it would submit a response to the agency.

Filed Under: Business/Financial News, News Well Tagged With: Gift Bans, Invacare, Warning Letter

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy